ABSTRACT Objective There is a lack of studies on seizure outcomes associated with ofatumumab therapy in patients for relapsing anti‐N‐methyl‐D‐aspartate (NMDA) receptor encephalitis. We aimed to evaluate long‐term seizure outcomes of ofatumumab therapy for relapsing anti‐NMDA receptor encephalitis.
Jian Wang, Mengjiao Li, Ping Kong
wiley +1 more source
Akshata Palve1, Nikita Pagare2, Gauri Mahajan3, Shweta Pandey4, Sujal Unikam5, Harshal Nathe6
openalex +1 more source
Necrotizing periodontitis in which oral symptoms led to diagnosis of HIV infection, with marked improvement in gingival ulceration and periodontal status following appropriate oral management: a case report [PDF]
Shoya Ueda +11 more
openalex +1 more source
Symptom management in cancer care: An evolutionary concept analysis for a digitally enabled collaborative framework. [PDF]
Yu W +5 more
europepmc +1 more source
microRNA‐7‐5p and α‐Synuclein SAA Predict Parkinson's Disease Phenoconversion
ABSTRACT Objective Corroborate blood neuron‐derived extracellular vesicle (NDEV) alpha‐synuclein (αSyn), the CSF αSyn seed amplification assay (αSyn‐SAA), and blood microRNA‐7‐5p (miR‐7‐5p) as markers for Parkinson's disease (PD) phenoconversion and determine if combining these markers would help select subjects who would be more likely to phenoconvert.
Shayan Zadegan +4 more
wiley +1 more source
Application of continuous care in patients with allergic rhinitis
CHEN Yanping
doaj
Mind-body exercise for symptom management in cancer: a systematic review and meta-analysis. [PDF]
Liu X +6 more
europepmc +1 more source
Systemic Extracerebral Atherosclerotic Burden and Dementia Risk After Incident Stroke
ABSTRACT Background Stroke survivors are at increased risk of dementia, but clinically accessible markers of risk heterogeneity remain limited. Previous studies have largely examined atherosclerotic disease in individual vascular beds rather than the overall burden of systemic extracerebral atherosclerosis.
Zhexuan Yu +4 more
wiley +1 more source
Glucagon‐Like Peptide‐1 Receptor Agonists in Multiple Sclerosis: A Topical Narrative Review
ABSTRACT The glucagon‐like peptide‐1 (GLP‐1) receptor agonists (RAs) are a relatively new class of drugs that were initially approved by the US Food and Drug Administration to improve glycemic control in patients with type 2 diabetes mellitus and, subsequently, weight reduction in patients with obesity.
Audrey Y. Chang, Farrah J. Mateen
wiley +1 more source

